Filing Details
- Accession Number:
- 0001209191-23-020395
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-21 19:15:04
- Reporting Period:
- 2023-03-17
- Accepted Time:
- 2023-03-21 19:15:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1445283 | Kineta Inc. | KA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1958184 | Shawn Iadonato | C/O Kineta, Inc. 219 Terry Ave. N., Suite 300 Seattle WA 98109 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-03-17 | 1,536 | $4.93 | 667,450 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-03-17 | 44 | $5.23 | 667,406 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-03-20 | 1,119 | $3.29 | 666,287 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 8,553 | Indirect | By IRA |
Footnotes
- Shares of the Issuer's Common Stock were sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's Common Stock in connection with the settlement of the vested portion of restricted stock units.
- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.22 to $5.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.20 to $3.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
